On track to become a leading European biotech
years of ground-breaking research and development with a first medicine on the market
year partnership signed with Gilead in 2019
An increasing global reach
employees globally
sites across Europe and the US
Innovative science to address patient needs is at the heart of our business
of employees work in R&D
of employees work in commercial
Targeting a range of conditions, including these underserved diseases
CROHN’S DISEASE
BLOOD CANCER
Our focus and commitment to patients will always remain at the center of everything we do with the aim to add years of life and quality of life of patients across the globe.
Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications.Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
For additional information, please visit https://www.glpg.com/ or follow us on LinkedIn or Twitter
Galapagos conducts Phase 1 trials in healthy volunteers in centers which are specifically equipped for this purpose, with the aim to test the safety, tolerability and …
We’re not only looking for scientists. We’re looking for pioneers in a wide range of domains: The best-in-class doctors, …
Our commitment to Corporate Social Responsibility (CSR) is intrinsically linked to our core mission: to discover and develop …
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos NV.
© 2022 Galapagos NV. All rights reserved.
GL-RA-FIL-202104-00008 12/22
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos NV.
© 2022 Galapagos NV. All rights reserved.
GL-RA-FIL-202104-00008 12/22
© Copyright 2021 Galapagos NV
You are about to leave this website and will be redirected to an external website. We are not responsible of that external website’s content. By continuing, you confirm that you have taken note of this.
